But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan's ageing Restasis potentially facing generic competition, there’s a lot to play for ...

Harrow's products compete against established generics, and it heavily relies on marketing and sales force expansion to drive ...

Pfizer and Allergan have confirmed that they will merge in a $160 billion deal, with Ireland-domiciled Allergan acquiring the US pharma giant, and re-naming itself Pfizer. The deal is the biggest ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 153,500 newsletter subscribers for 21 days.